Although nuclear imaging is not a first-line investigation, it shows promise to differentiate between cardiac amyloidosis subtypes (cardiac AL and transthyretin-related cardiac amyloidosis (ATTR, mutant and wild types)), which has important therapeutic and prognostic implications [10]. The gene discussed is TTR; the disease is cardiac amyloidosis.